OMER — Omeros Corporation

Omeros Corporation Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Income: Omeros reported a net income of $86.5 million ($1.22 per share) for Q4 2025, a significant turnaround from a net loss of $30.9 million ($0.47 per share) in Q3 2025.
• Transaction Gain: The results included a net gain of $237.6 million from the sale of zaltenibart to Novo Nordisk.
• Non-GAAP Adjusted Income: Excluding a $136 million noncash charge related to convertible notes, the non-GAAP adjusted net income was $222.5 million ($3.14 per share).
• Cash Position: As of December 31, 2025, cash and investments totaled $171.8 million, up $135.7 million from Q3 2025.
• Debt Repayment: The company repaid its $67.1 million term loan and $17.1 million in 2026 convertible notes, leaving only $70.8 million in 2029 convertible notes outstanding.

2. Strategic Updates and Business Highlights

• FDA Approval: Received FDA approval for YARTEMLEA (narsoplimab) for treating TA-TMA, marking it as the first approved treatment for this condition.
• Commercial Launch: The launch of YARTEMLEA began in January 2026, with initial sales occurring shortly after distribution to hospitals. The drug is priced at approximately $36,000 per vial.
• Partnership with Novo Nordisk: The asset sale to Novo Nordisk includes an upfront payment of $240 million, with potential total value up to $2.1 billion in milestones and royalties.
• Development Pipeline: Omeros is advancing its MASP-2 small molecule program and exploring additional indications for YARTEMLEA, including ARDS and solid organ transplant-related TMA.

3. Forward Guidance and Outlook

• Financial Sustainability: Omeros expects the YARTEMLEA program to be financially self-sustaining in 2026 and anticipates achieving positive cash flow by 2027.
• Q1 2026 Expectations: Operating expenses are expected to remain comparable to Q4 2025, with an increase in sales and marketing expenses for YARTEMLEA. Revenue guidance is not provided due to the early stage of the launch.

4. Challenges and Points of Concern

• Noncash Charges: The significant noncash charge related to the mark-to-market adjustment on convertible notes introduces volatility in reported results.
• Market Adoption: While initial feedback on YARTEMLEA has been positive, the company faces the challenge of establishing formulary coverage and physician adoption across transplant centers.
• Regulatory Risks: The pending marketing authorization application with the European Medicines Agency (EMA) poses potential uncertainties regarding approval timelines and market entry.

5. Notable Q&A Insights

• Formulary Approvals: The company is optimistic about continuing P&T committee approvals for YARTEMLEA, with 50% of the top 10 transplant centers already on formulary.
• Real-World Usage: Early usage data indicates a split of approximately 70% once-weekly and 30% twice-weekly dosing, with expectations for increased twice-weekly usage as education efforts progress.
• Patient Access: All pre-authorization requests for YARTEMLEA have been approved by third-party payers, facilitating access for patients.
• Milestone Confidence: Management expressed high confidence in receiving the $100 million milestone from Novo Nordisk, although specific triggers for this milestone were not disclosed.

Overall, Omeros Corporation demonstrated strong financial performance in Q4 2025, driven by strategic partnerships and product approvals, while navigating challenges related to market adoption and regulatory processes.